NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

病毒載體/質粒DNA生產的全球市場分析(2021-2031年):按載體類型(腺病毒,逆轉錄病毒,質粒DNA,AAV,慢病毒),用途,疾病,最終用途,地區另一個預測,主要公司,從新型冠狀病毒感染(COVID-19)的恢復方案

Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031: Forecasts by Vector Types (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus), Application, Disease, End-use, Region, Leading Companies, COVID-19 Recovery Scenarios

出版商 Visiongain Ltd 商品編碼 983588
出版日期 內容資訊 英文 586 Pages
商品交期: 最快1-2個工作天內
價格
病毒載體/質粒DNA生產的全球市場分析(2021-2031年):按載體類型(腺病毒,逆轉錄病毒,質粒DNA,AAV,慢病毒),用途,疾病,最終用途,地區另一個預測,主要公司,從新型冠狀病毒感染(COVID-19)的恢復方案 Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031: Forecasts by Vector Types (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus), Application, Disease, End-use, Region, Leading Companies, COVID-19 Recovery Scenarios
出版日期: 2020年11月24日內容資訊: 英文 586 Pages
簡介

本報告分析了全球病毒載體和質粒DNA的製造市場,並分析了產品概況,市場的基本結構/最新情況,主要的促進/抑制因素以及估計/預測的市場規模(未來11年間。總結並提供了按媒介類型/用途/疾病/最終用途和地區/主要國家/地區,主要公司的概況,COVID-19的影響情況等得出的詳細趨勢。

目錄

第1章分析概述

第2章執行摘要

第3章行業考慮

  • 促進因素
    • 基因治療和病毒載體的強大管道
    • 由於需求增長,每個製造商的生產能力得以擴展
  • 抑制因素
    • 高昂的治療費用
    • 製造商遇到的瓶頸
  • 市場機會
    • 同種/自體細胞療法發展的興起
    • COVID-19疫苗生產的有利機會
    • 越來越多地用作神經科學的臨床前工具
  • 克服挑戰的策略
  • 波特的五種力量分析
  • SWOT分析

第4章病毒載體生產能力:作圖分析

  • CMO的病毒載體生產能力
  • 潔淨室套件設施:主要病毒載體生產商

第5章病毒載體生產和利潤分析

  • 簡介
  • ATMP載體和製造平台
  • 用於細胞和基因治療的病毒載體的監管挑戰

第6章病毒載體製造:過程經濟方面的考慮和挑戰

  • 與製造業相關的技術進步
  • 穩定的生產細胞系
  • 用穩定的生產細胞系解決細胞毒性問題
  • 使用穩定的生產者細胞係時,工藝開發的注意事項是什麼?
  • 穩定的生產細胞系如何提高CGT的生產效率並降低成本?
    • 簡化上游生產流程
    • 減少試劑成本和人工成本
    • 增加了擴展的靈活性
  • 何時從瞬時轉染切換到穩定的生產者細胞株以生產LVV?
  • 成本考慮
  • 監管預期

第7章病毒載體生產過程分析

  • 簡介
  • 上游過程(通過轉染使細胞解凍和擴增)
  • 下游流程(通過精煉收穫)
  • 配方/穩定化和填充/完成
  • 病毒分析
  • 病毒載體生產:設施需求
  • 監管標準需求
  • 勞動力發展與需求

第8章病毒載體/質粒DNA製造市場:按載體類型

  • 腺病毒(2021-2031)
    • 市場概況
    • 市場復甦場景(V形/U形/W形/L形恢復)
  • 逆轉錄病毒(2021-2031)
  • 質粒DNA(2021-2031)
  • 腺伴隨病毒(AAV)(2021-2031)
  • 扳手病毒(2021-2031)
  • 其他(2021-2031)

第9章病毒載體/質粒DNA製造市場:按應用

  • 反義RNAi(2021-2031)
  • 基因療法(2021-2031)
  • 細胞療法(2021-2031)
  • 疫苗(2021-2031)

第10章病毒載體/質粒DNA製造市場:按疾病分類

  • 腫瘤(2021-2031)
  • 遺傳性疾病(2021-2031)
  • 傳染病(2021-2031)
  • 其他疾病(2021-2031)

第11章病毒載體/質粒DNA製造市場:最終用途

  • 製藥和生物製藥公司(2021-2031)
  • 研究所(2021-2031)

第12章病毒載體/質粒DNA製造市場:按地區/國家(2021-2031)

  • 各地區趨勢預測(2021-2031)
  • 區域恢復情景(V形/U形/W形/L形恢復)

第13章北美病毒載體/質粒DNA製造市場

  • 市場預測:按國家分類(2021-2031)
    • 恢復方案(V形/U形/W形/L形恢復)
  • 市場預測:按向量類型(2021-2031)
  • 市場預測:按用途分類(2021-2031)
  • 市場預測:按疾病分類(2021-2031)
  • 市場預測:按最終用途劃分(2021-2031)
  • 美國市場
    • 恢復方案(V形/U形/W形/L形恢復)(2021-2031)
    • 市場預測:按向量類型(2021-2031)
    • 市場預測:按用途分類(2021-2031)
    • 市場預測:按疾病分類(2021-2031)
    • 市場預測:按最終用途劃分(2021-2031)
  • 加拿大市場

第14章歐洲病毒載體/質粒DNA製造市場

  • 市場預測:按國家分類(2021-2031)
    • 恢復方案(V形/U形/W形/L形恢復)
  • 市場預測:按向量類型(2021-2031)
  • 市場預測:按用途分類(2021-2031)
  • 市場預測:按疾病分類(2021-2031)
  • 市場預測:按最終用途劃分(2021-2031)
  • 德國市場
  • 英國市場
  • 其他歐洲國家的市場

第15章亞太病毒載體/質粒DNA製造市場

  • 市場預測:按國家分類(2021-2031)
    • 恢復方案(V形/U形/W形/L形恢復)
  • 市場預測:按向量類型(2021-2031)
  • 市場預測:按用途分類(2021-2031)
  • 市場預測:按疾病分類(2021-2031)
  • 市場預測:按最終用途劃分(2021-2031)
  • 中國市場
  • 日本市場
  • 印度市場
  • 亞太其他國家/地區的市場

第16章拉丁美洲病毒載體/質粒DNA製造市場

  • 市場預測:按國家分類(2021-2031)
    • 恢復方案(V形/U形/W形/L形恢復)
  • 市場預測:按向量類型(2021-2031)
  • 市場預測:按用途分類(2021-2031)
  • 市場預測:按疾病分類(2021-2031)
  • 市場預測:按最終用途劃分(2021-2031)
  • 巴西市場
  • 其他拉丁美洲國家的市場

第17章中東/非洲病毒載體/質粒DNA製造市場

  • 市場預測:按國家分類(2021-2031)
    • 恢復方案(V形/U形/W形/L形恢復)
  • 市場預測:按向量類型(2021-2031)
  • 市場預測:按用途分類(2021-2031)
  • 市場預測:按疾病分類(2021-2031)
  • 市場預測:按最終用途劃分(2021-2031)
  • 南非市場
  • 其他中東和非洲國家的市場

第18章公司簡介

  • 默克(Merck KGaA)
    • 公司的最新趨勢(2020年)
    • 公司簡介
    • 財務分析(2015-2019)
    • 產品比較分析
    • 最新趨勢
  • Lonza
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc
  • Cobra Biologics Ltd.
  • Brammer Bio
  • Waisman Biomanufacturing
  • Genezen
  • YPOSKESI
  • Advanced BioScience Laboratories, Inc. (ABL, Inc.)
  • Novasep Holding S.A.S
  • ATVIO Biotech Ltd
  • Vigene Biosciences, Inc
  • Cytiva
  • CEVEC Pharmaceuticals GmbH
  • Batavia Biosciences B.V
  • Biovian Oy
  • Wuxi AppTec Co., Ltd.
  • VGXI, Inc.
  • Paragon Bioservices, Inc.
  • Miltenyi Biotec GmbH
  • SIRION Biotech GmbH
  • Virovek Incorporation
  • BioNTech IMFS GmbH
  • VIVEbiotech S.L.
  • Creative Biogene
  • Vibalogics GmbH
  • Cell and Gene Therapy Catapult
  • BlueBird Bio
  • Addgene, Inc.
  • Aldevron, L.L.C.
  • Audentes Therapeutics
  • BioMarin Pharmaceutical

第19章結論

目錄
Product Code: PHA1020

Title:
Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031
Forecasts by Vector Types (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), Application (Antisense & RNAi, Gene Therapy, Cell Therapy, Vaccinology), Disease (Oncology, Genetic Disorders, Infectious Diseases, Others), End-use (Pharma and Biopharma Companies, Research Institutes), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). PLUS Analysis of Leading Viral Vectors & Plasmid DNA Manufacturing Companies AND COVID-19 Recovery Scenarios.

What are the Regulatory Challenges for Viral Vectors for Cell and Gene Therapy?

The processing of viral vectors is complex. It is difficult to scale up legacy technologies adopted from the academic research side, for one thing. Technology issues combined with talent shortages are also a further bottleneck to capacity expansion. The demand for relatively young cells and gene therapy is extremely fragmented worldwide. In order to assist with viral vector demands and shortages, few contract research and development organizations (CMO/CROs) are commercially scaled. Just a handful of larger corporations are capable of manufacturing on a commercial scale, and there are few solutions that enable businesses to increase their own capability.

What are the Technological Advancements in Manufacturing of Viral Vectors?

Gene therapies are incredibly costly in this early stage of growth, but they deliver the promise of being curative in a single phase, thus reducing overall healthcare costs. Many disorders may be treated by recent advances in the discovery of genes responsible for diseases and the use of gene editing technology for genetic modification. As a consequence, biopharmaceutical manufacturers are focused on the rapid market deployment of goods. Their initiatives include designing facilities and supply chains to meet the growing demands of patients worldwide, lowering production costs, the effectiveness and efficacy of these new modalities, and improving patient safety by minimizing the possible side effects of gene therapy drugs.

UNIQUE COVID-19 VARIATIONS- only available in this Visiongain report are dedicated analysis of 4 different rebound scenarios of how the market will develop - no matter how COVID-19 affects the economy.

Which Factors are Fueling Viral Vectors and Plasmid DNA Manufacturing Industry Growth?

  • Robust Pipeline for Gene Therapy and Viral Vectors
  • Increasing Capacities by Manufacturers Owing to Rising Demand

Which Factors are Restraining Growth?

  • High Cost of Therapies
  • Bottlenecks Experienced by Manufacturers

What are the Market Opportunities & Threats?

  • Rise in the Development of Allogenic and Autologous Cell Therapy
  • Lucrative opportunity in manufacturing of COVID-19 vaccine
  • Increasing Applications as Preclinical Tool in Neuroscience Research

How do prominent players strengthen their position throughout the world?

You must read this newly updated report if you are involved in this sector. The report from Visiongain shows you potential revenues up to 2031, evaluate information, trends, opportunities and business outlooks.

Discover how to stay ahead

Our 580+ page report provides 500+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Viral Vectors and Plasmid DNA Manufacturing Market. See how to exploit the opportunities.

Forecasts to 2031 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, Porter's Analysis, product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Vector Type

  • Adenovirus
  • Retrovirus
  • Plasmid DNA
  • AAV
  • Lentivirus
  • Others

Application

  • Antisense & RNAi
  • Gene Therapy
  • Cell Therapy
  • Vaccinology

Disease

  • Oncology
  • Genetic Disorders
  • Infectious Diseases
  • Others

End-Use

  • Pharma and Biopharma Companies
  • Research Institutes

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 9 leading national markets:

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Rest of MEA

Leading companies and the potential for market growth

Overall world revenue for Viral Vectors and Plasmid DNA Manufacturing Market will surpass $xx million in 2020, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which regions hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Prospects for established firms and those seeking to enter the market- including company profiles for 32 of the major companies involved in the Viral Vectors and Plasmid DNA Manufacturing Market. Some of the companies profiled in this report include Merck KGaA, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Cobra Biologics Ltd., Brammer Bio, Waisman Biomanufacturing, Genezen, YPOSKESI, Advanced BioScience Laboratories, Inc. (ABL, Inc.), Novasep Holding S.A.S, ATVIO Biotech Ltd, Vigene Biosciences, Inc., Cytiva, CEVEC Pharmaceuticals GmbH, Batavia Biosciences B.V, Biovian Oy, Wuxi AppTec Co., Ltd., VGXI, Inc., Paragon Bioservices, Inc., Miltenyi Biotec GmbH, SIRION Biotech GmbH, Virovek Incorporation, BioNTech IMFS GmbH, VIVEbiotech S.L., Creative Biogene, Vibalogics GmbH, Cell and Gene Therapy Catapult, BlueBird Bio, Addgene, Inc., Aldevron, L.L.C., Audentes Therapeutics, and BioMarin Pharmaceutical.

Key Questions Answered by this Report:

  • What is the current size of the overall global viral vectors and plasmid DNA manufacturing market? How much will this market be worth from 2021 to 2031?
  • What are the main drivers and restraints that will shape the overall viral vectors and plasmid DNA manufacturing market over the next ten years?
  • What are the main segments within the overall viral vectors and plasmid DNA manufacturing market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why?
  • What factors will affect that industry and market over the next ten years?
  • What are the largest national markets for the world viral vectors and plasmid DNA manufacturing? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2031?
  • How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
  • Which are the leading companies and what are their activities, results, developments, and prospects?
  • What are the main trends that will affect the world Viral Vectors and Plasmid DNA Manufacturing market between 2021 and 2031?
  • What are the main strengths, weaknesses, opportunities, and threats for the market?
  • How will the global viral vectors and plasmid DNA manufacturing market evolve over the forecasted period, 2021 to 2031?
  • How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.

Visiongain's study is intended for everybody needing commercial analyses for the Global Viral Vectors and Plasmid DNA Manufacturing Market and leading companies. You will find data, trends and predictions.

Buy our report today Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031: Forecasts by Vector Types (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), Application (Antisense & RNAi, Gene Therapy, Cell Therapy, Vaccinology), Disease (Oncology, Genetic Disorders, Infectious Diseases, Others), End-use (Pharma and Biopharma Companies, Research Institutes), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). PLUS Analysis of Leading Viral Vectors & Plasmid DNA Manufacturing Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed - order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Introduction to Viral Vectors and Plasmid DNA Manufacturing Market
  • 1.2 Why You Should Read This Report
  • 1.3 What This Report Delivers
  • 1.4 Key Questions Answered By This Analytical Report Include:
  • 1.5 Who is This Report For?
  • 1.6 Methodology
    • 1.6.1 COVID-19 Impact: Recovery Scenarios
    • 1.6.2 Market Evaluation & Forecasting Methodology
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2 Executive Summary

3 Industry Insights

  • 3.1 Drivers
    • 3.1.1 Robust Pipeline for Gene Therapy and Viral Vectors
    • 3.1.2 Increasing Capacities by Manufacturers Owing to Rising Demand
  • 3.2 Restraints
    • 3.2.1 High Cost of Therapies
    • 3.2.2 Bottlenecks Experienced by Manufacturers
  • 3.3 Opportunities
    • 3.3.1 Rise in the Development of Allogenic and Autologous Cell Therapy
    • 3.3.2 Lucrative opportunity in manufacturing of COVID-19 vaccine
    • 3.3.3 Increasing Applications As Preclinical Tool In Neuroscience Research
  • 3.4 Strategies to Overcome Challenges
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Buyer Power
    • 3.5.2 Supplier Power
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitute
    • 3.5.5 Threat of New Entrants
  • 3.6 SWOT Analysis
    • 3.6.1 Strengths
    • 3.6.2 Weaknesses
    • 3.6.3 Opportunities
    • 3.6.4 Threats

4 Viral Vector Production Capacity Mapping Analysis

  • 4.1 CMOs Capacity for Viral Vector Manufacturing
  • 4.2 Cleanroom Suites Facilities: Leading Viral Vector Manufacturers

5 Viral Vector Production & Yield Analysis

  • 5.1 Introduction
  • 5.2 ATMP Vectors and Manufacturing Platforms
  • 5.3 Regulatory Challenges for Viral Vectors for Cell and Gene Therapy

6 Viral Vector Manufacturing: Process Economic Considerations and Challenges

  • 6.1 Technological Advances in Manufacturing
  • 6.2 Stable Producer Cell Lines
  • 6.3 Addressing the Challenges of Cytotoxicity with Stable Producer Lines
  • 6.4 What are the Process Development Considerations for the Use of Stable Producer Lines?
  • 6.5 How Do Stable Producer Cell Lines Create Efficiencies and Reduce Costs in the Production of CGTs?
    • 6.5.1 Simplified Upstream Production
    • 6.5.2 Lower Costs for Reagents and Labour
    • 6.5.3 More Flexibility for Scale Up
  • 6.6 When is the Time to Switch from Transient Transfection to Stable Producer Cell Lines for LVV Manufacturing?
  • 6.7 Cost Considerations
  • 6.8 Regulatory Expectations

7 Viral Vectors Production Process Analysis

  • 7.1 Introduction
  • 7.2 Upstream Unit Operations (Cell Thaw and Expansion Through Transfection)
  • 7.3 Downstream Unit Operations (Harvest Through Purification)
  • 7.4 Formulation/Stability and Fill/Finish
  • 7.5 Viral Analytics
  • 7.6 Viral Vector Production: Facilities Needs
  • 7.7 Regulatory Standard Needs
  • 7.8 Workforce Development and Needs

8 Viral Vectors and Plasmid DNA Manufacturing Market by Vector Types

  • 8.1 Adenovirus Segment Market Forecast, 2021-2031
    • 8.1.1 Introduction
    • 8.1.2 Adenoviruses are Promising Vaccine Adjuvant
    • 8.1.3 Recovery Scenarios (V, U, W, L)
  • 8.2 Retrovirus Segment Market Forecast, 2021-2031
    • 8.2.1 Introduction
    • 8.2.2 Recovery Scenarios (V, U, W, L)
  • 8.3 Plasmid DNA Segment Market Forecast, 2021-2031
    • 8.3.1 Introduction
    • 8.3.2 Recovery Scenarios (V, U, W, L)
  • 8.4 AAV Segment Market Forecast, 2021-2031
    • 8.4.1 Introduction
    • 8.4.2 Recovery Scenarios (V, U, W, L)
  • 8.5 Lentivirus Segment Market Forecast, 2021-2031
    • 8.5.1 Introduction
    • 8.5.2 Recovery Scenarios (V, U, W, L)
  • 8.6 Others Segment Market Forecast, 2021-2031
    • 8.6.1 Recovery Scenarios (V, U, W, L)

9 Viral Vectors and Plasmid DNA Manufacturing Market by Application

  • 9.1 Antisense & RNAi Segment Market Forecast, 2021-2031
    • 9.1.1 Introduction
    • 9.1.2 Recovery Scenarios (V, U, W, L)
  • 9.2 Gene Therapy Segment Market Forecast, 2021-2031
    • 9.2.1 Introduction
    • 9.2.2 Recovery Scenarios (V, U, W, L)
  • 9.3 Cell Therapy Segment Market Forecast, 2021-2031
    • 9.3.1 Introduction
    • 9.3.2 Recovery Scenarios (V, U, W, L)
  • 9.4 Vaccinology Segment Market Forecast, 2021-2031
    • 9.4.1 Introduction
    • 9.4.2 Recovery Scenarios (V, U, W, L)

10 Viral Vectors and Plasmid DNA Manufacturing Market by Disease

  • 10.1 Oncology Segment Market Forecast, 2021-2031
    • 10.1.1 Introduction
    • 10.1.2 Recovery Scenarios (V, U, W, L)
  • 10.2 Genetic Disorders Segment Market Forecast, 2021-2031
    • 10.2.1 Introduction
    • 10.2.2 Recovery Scenarios (V, U, W, L)
  • 10.3 Infectious Diseases Segment Market Forecast, 2021-2031
    • 10.3.1 Introduction
    • 10.3.2 Recovery Scenarios (V, U, W, L)
  • 10.4 Others Segment Market Forecast, 2021-2031
    • 10.4.1 Recovery Scenarios (V, U, W, L)

11 Viral Vectors and Plasmid DNA Manufacturing Market by End-Use

  • 11.1 Pharma and Biopharma Companies Segment Market Forecast, 2021-2031
    • 11.1.1 Introduction
    • 11.1.2 Recovery Scenarios (V, U, W, L)
  • 11.2 Research Institutes Segment Market Forecast, 2021-2031
    • 11.2.1 Introduction
    • 11.2.2 Recovery Scenarios (V, U, W, L)

12 Regional and Leading National Viral Vectors and Plasmid DNA Manufacturing Market Forecasts 2021-2031

  • 12.1 Global Viral Vectors and Plasmid DNA Manufacturing Market by Region Forecast 2021-2031
  • 12.2 Recovery Scenarios (V, U, W, L)

13 North America Viral Vectors and Plasmid DNA Manufacturing Market

  • 13.1 North America Viral Vectors and Plasmid DNA Manufacturing Market by Country Forecast 2021-2031
    • 13.1.1 Recovery Scenarios (V, U, W, L)
  • 13.2 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
    • 13.2.1 Recovery Scenarios (V, U, W, L): North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 13.3 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
    • 13.3.1 Recovery Scenarios (V, U, W, L): North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 13.4 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
    • 13.4.1 Recovery Scenarios (V, U, W, L): North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 13.5 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
    • 13.5.1 Recovery Scenarios (V, U, W, L): North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 13.6 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 13.6.1 Recovery Scenarios (V, U, W, L): U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 13.7 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 13.8 U.S. Viral Vectors and Plasmid DNA Manufacturing
  • 13.9 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 13.10 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 13.11 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 13.12 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 13.12.1 Introduction
    • 13.12.2 Recovery Scenarios (V, U, W, L): Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 13.13 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 13.14 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 13.15 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 13.16 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031

14 Europe Viral Vectors and Plasmid DNA Manufacturing Market

  • 14.1 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Country Forecast 2021-2031
    • 14.1.1 Recovery Scenarios (V, U, W, L)
  • 14.2 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
    • 14.2.1 Recovery Scenarios (V, U, W, L): Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 14.3 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
    • 14.3.1 Recovery Scenarios (V, U, W, L): Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 14.4 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
    • 14.4.1 Recovery Scenarios (V, U, W, L): Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 14.5 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
    • 14.5.1 Recovery Scenarios (V, U, W, L): Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 14.6 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 14.6.1 Introduction
    • 14.6.2 Recovery Scenarios (V, U, W, L): Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 14.7 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 14.8 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 14.9 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 14.10 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 14.11 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 14.11.1 Introduction
    • 14.11.2 Future Capacity and Expansion in UK
    • 14.11.3 Recovery Scenarios (V, U, W, L): UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 14.12 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 14.13 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 14.14 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 14.15 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 14.16 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 14.16.1 Recovery Scenarios (V, U, W, L): Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 14.17 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 14.18 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 14.19 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 14.20 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031

15 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market

  • 15.1 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Country Forecast 2021-2031
    • 15.1.1 Recovery Scenarios (V, U, W, L)
  • 15.2 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
    • 15.2.1 Recovery Scenarios (V, U, W, L): Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 15.3 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
    • 15.3.1 Recovery Scenarios (V, U, W, L): Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 15.4 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
    • 15.4.1 Recovery Scenarios (V, U, W, L): Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 15.5 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
    • 15.5.1 Recovery Scenarios (V, U, W, L): Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 15.6 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 15.6.1 Announcement of GenScript to Operate Plasmid Facility in China
    • 15.6.2 Recovery Scenarios (V, U, W, L): China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 15.7 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 15.8 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 15.9 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 15.10 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 15.11 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 15.11.1 Japan is the Third Biggest Pharmaceutical Industry Globally
    • 15.11.2 Recovery Scenarios (V, U, W, L): Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 15.12 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 15.13 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 15.14 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 15.15 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 15.16 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 15.16.1 India to Witness the Highest Growth Rate Owing to Rising Government Support Towards Biotech Sector
    • 15.16.2 Recovery Scenarios (V, U, W, L): India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 15.17 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 15.18 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 15.19 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 15.20 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 15.21 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 15.21.1 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 15.22 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 15.23 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 15.24 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 15.25 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031

16 Latin America Viral Vectors and Plasmid DNA Manufacturing Market

  • 16.1 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Country Forecast 2021-2031
    • 16.1.1 Recovery Scenarios (V, U, W, L)
  • 16.2 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
    • 16.2.1 Recovery Scenarios (V, U, W, L): Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 16.3 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
    • 16.3.1 Recovery Scenarios (V, U, W, L): Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 16.4 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
    • 16.4.1 Recovery Scenarios (V, U, W, L): Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 16.5 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
    • 16.5.1 Recovery Scenarios (V, U, W, L): Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 16.6 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 16.6.1 Brazil Became First Country in Latin America to Approve Commercialization of Gene Therapy Products
    • 16.6.2 Recovery Scenarios (V, U, W, L): Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 16.7 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 16.8 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 16.9 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 16.10 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 16.11 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 16.11.1 Recovery Scenarios (V, U, W, L): Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 16.12 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 16.13 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 16.14 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 16.15 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031

17 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market

  • 17.1 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market by Country Forecast 2021-2031
    • 17.1.1 Recovery Scenarios (V, U, W, L)
  • 17.2 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
    • 17.2.1 Recovery Scenarios (V, U, W, L): Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 17.3 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
    • 17.3.1 Recovery Scenarios (V, U, W, L): Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 17.4 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
    • 17.4.1 Recovery Scenarios (V, U, W, L): Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 17.5 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
    • 17.5.1 Recovery Scenarios (V, U, W, L): Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 17.6 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 17.6.1 South African Government Focussing to Strengthen Biotech Industry
    • 17.6.2 Recovery Scenarios (V, U, W, L): South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 17.7 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 17.8 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 17.9 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 17.10 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031
  • 17.11 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
    • 17.11.1 Recovery Scenarios (V, U, W, L): Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031
  • 17.12 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031
  • 17.13 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031
  • 17.14 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031
  • 17.15 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031

18 Company Profiles

  • 18.1 Merck KGaA
    • 18.1.1 Company Snapshot, 2020
    • 18.1.2 Company Overview
    • 18.1.3 Financial Analysis, 2015-2019
    • 18.1.4 Product Benchmarking
    • 18.1.5 Recent Developments
  • 18.2 Lonza
    • 18.2.1 Company Snapshot, 2020
    • 18.2.2 Company Overview
    • 18.2.3 Financial Analysis, 2015-2019
    • 18.2.4 Product Benchmarking
    • 18.2.5 Recent Developments
  • 18.3 FUJIFILM Diosynth Biotechnologies U.S.A., Inc
    • 18.3.1 Company Snapshot, 2020
    • 18.3.2 Company Overview
    • 18.3.3 Financial Analysis, 2015-2019
    • 18.3.4 Product Benchmarking
    • 18.3.5 Recent Developments
  • 18.4 Cobra Biologics Ltd.
    • 18.4.1 Company Snapshot, 2020
    • 18.4.2 Company Overview
    • 18.4.3 Product Benchmarking
    • 18.4.4 Recent Developments
  • 18.5 Brammer Bio
    • 18.5.1 Company Snapshot, 2020
    • 18.5.2 Company Overview
    • 18.5.3 Product Benchmarking
    • 18.5.4 Recent Developments
  • 18.6 Waisman Biomanufacturing
    • 18.6.1 Company Snapshot, 2020
    • 18.6.2 Company Overview
    • 18.6.3 Product Benchmarking
  • 18.7 Genezen
    • 18.7.1 Company Snapshot, 2020
    • 18.7.2 Company Overview
    • 18.7.3 Product Benchmarking
    • 18.7.4 Recent Developments
  • 18.8 YPOSKESI
    • 18.8.1 Company Snapshot, 2020
    • 18.8.2 Company Overview
    • 18.8.3 Product Benchmarking
    • 18.8.4 Recent Developments
  • 18.9 Advanced BioScience Laboratories, Inc. (ABL, Inc.)
    • 18.9.1 Company Snapshot, 2020
    • 18.9.2 Company Overview
    • 18.9.3 Product Benchmarking
    • 18.9.4 Recent Developments
  • 18.10 Novasep Holding S.A.S
    • 18.10.1 Company Snapshot, 2020
    • 18.10.2 Company Overview
    • 18.10.3 Product Benchmarking
    • 18.10.4 Recent Developments
  • 18.11 ATVIO Biotech Ltd
    • 18.11.1 Company Snapshot, 2020
    • 18.11.2 Company Overview
    • 18.11.3 Product Benchmarking
    • 18.11.4 Recent Developments
  • 18.12 Vigene Biosciences, Inc
    • 18.12.1 Company Snapshot, 2020
    • 18.12.2 Company Overview
    • 18.12.3 Product Benchmarking
    • 18.12.4 Recent Developments
  • 18.13 Cytiva
    • 18.13.1 Company Snapshot, 2020
    • 18.13.2 Company Overview
    • 18.13.3 Financial Analysis, 2015-2019
    • 18.13.4 Recent Developments
  • 18.14 CEVEC Pharmaceuticals GmbH
    • 18.14.1 Company Snapshot, 2020
    • 18.14.2 Company Overview
    • 18.14.3 Product Benchmarking
    • 18.14.4 Recent Developments
  • 18.15 Batavia Biosciences B.V
    • 18.15.1 Company Snapshot, 2020
    • 18.15.2 Company Overview
    • 18.15.3 Product Benchmarking
    • 18.15.4 Recent Developments
  • 18.16 Biovian Oy
    • 18.16.1 Company Snapshot, 2020
    • 18.16.2 Company Overview
    • 18.16.3 Product Benchmarking
  • 18.17 Wuxi AppTec Co., Ltd.
    • 18.17.1 Company Snapshot, 2020
    • 18.17.2 Company Overview
    • 18.17.3 Product Benchmarking
    • 18.17.4 Recent Developments
  • 18.18 VGXI, Inc.
    • 18.18.1 Company Snapshot, 2020
    • 18.18.2 Company Overview
    • 18.18.3 Product Benchmarking
  • 18.19 Paragon Bioservices, Inc.
    • 18.19.1 Company Snapshot, 2020
    • 18.19.2 Company Overview
    • 18.19.3 Product Benchmarking
    • 18.19.4 Recent Developments
  • 18.20 Miltenyi Biotec GmbH
    • 18.20.1 Company Snapshot, 2020
    • 18.20.2 Company Overview
  • 18.21 SIRION Biotech GmbH
    • 18.21.1 Company Snapshot, 2020
    • 18.21.2 Company Overview
    • 18.21.3 Product Benchmarking
  • 18.22 Virovek Incorporation
    • 18.22.1 Company Snapshot, 2020
    • 18.22.2 Company Overview
    • 18.22.3 Product Benchmarking
  • 18.23 BioNTech IMFS GmbH
    • 18.23.1 Company Snapshot, 2020
    • 18.23.2 Company Overview
    • 18.23.3 Product Benchmarking
  • 18.24 VIVEbiotech S.L.
    • 18.24.1 Company Snapshot, 2020
    • 18.24.2 Company Overview
    • 18.24.3 Product Benchmarking
    • 18.24.4 Recent Developments
  • 18.25 Creative Biogene
    • 18.25.1 Company Snapshot, 2020
    • 18.25.2 Company Overview
    • 18.25.3 Product Benchmarking
    • 18.25.4 Recent Developments
  • 18.26 Vibalogics GmbH
    • 18.26.1 Company Snapshot, 2020
    • 18.26.2 Company Overview
    • 18.26.3 Product Benchmarking
    • 18.26.4 Recent Developments
  • 18.27 Cell and Gene Therapy Catapult
    • 18.27.1 Company Snapshot, 2020
    • 18.27.2 Company Overview
  • 18.28 BlueBird Bio
    • 18.28.1 Company Snapshot, 2020
    • 18.28.2 Company Overview
  • 18.29 Addgene, Inc.
    • 18.29.1 Company Snapshot, 2020
    • 18.29.2 Company Overview
    • 18.29.3 Product Benchmarking
    • 18.29.4 Recent Developments
  • 18.30 Aldevron, L.L.C.
    • 18.30.1 Company Snapshot, 2020
    • 18.30.2 Company Overview
    • 18.30.3 Product Benchmarking
  • 18.31 Audentes Therapeutics
    • 18.31.1 Company Snapshot, 2020
    • 18.31.2 Company Overview
    • 18.31.3 Recent Developments
  • 18.32 BioMarin Pharmaceutical
    • 18.32.1 Company Snapshot, 2020
    • 18.32.2 Company Overview
    • 18.32.3 Financial Analysis, 2015-2019
    • 18.32.4 Recent Developments

19 Conclusion

  • 19.1 Concluding Remarks
  • 19.2 Choosing a Cell Culture Technology
  • 19.3 Increased Urgency In Addressing Manufacturing Challenges

List of Tables

  • Table 1 Global Viral Vectors and Plasmid DNA Manufacturing Market Snapshot, 2020 & 2031 (US$ million, CAGR %)
  • Table 2 Advantages and Disadvantages of Adeno-Associated Virus Vectors
  • Table 3 Key Factors Affecting the Bargaining Power of Buyer
  • Table 4 Key Factors Affecting the Bargaining Power of Suppliers
  • Table 5 Key Factors Affecting the Industry Rivalry
  • Table 6 Key Factors Affecting the Threat of Substitutes
  • Table 7 Key Factors Affecting the Threat of New Entrants
  • Table 8 CMOs Capacity for Viral Vector Manufacturing
  • Table 9 Cleanroom Suites Facilities
  • Table 1 Global Viral Vectors and Plasmid DNA Manufacturing Market for Adenovirus Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 2 Global Viral Vectors and Plasmid DNA Manufacturing Market for Adenovirus Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 Global Viral Vectors and Plasmid DNA Manufacturing Market for Adenovirus Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 Global Viral Vectors and Plasmid DNA Manufacturing Market for Adenovirus Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 Global Viral Vectors and Plasmid DNA Manufacturing Market for Adenovirus Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 6 Global Viral Vectors and Plasmid DNA Manufacturing Market for Retrovirus Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 7 Global Viral Vectors and Plasmid DNA Manufacturing Market for Retrovirus Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 8 Global Viral Vectors and Plasmid DNA Manufacturing Market for Retrovirus Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 9 Global Viral Vectors and Plasmid DNA Manufacturing Market for Retrovirus Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 10 Global Viral Vectors and Plasmid DNA Manufacturing Market for Retrovirus Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 11 Global Viral Vectors and Plasmid DNA Manufacturing Market for Plasmid DNA Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 12 Global Viral Vectors and Plasmid DNA Manufacturing Market for Plasmid DNA Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 13 Global Viral Vectors and Plasmid DNA Manufacturing Market for Plasmid DNA Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 14 Global Viral Vectors and Plasmid DNA Manufacturing Market for Plasmid DNA Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 15 Global Viral Vectors and Plasmid DNA Manufacturing Market for Plasmid DNA Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 16 Global Viral Vectors and Plasmid DNA Manufacturing Market for AAV Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 17 Global Viral Vectors and Plasmid DNA Manufacturing Market for AAV Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 18 Global Viral Vectors and Plasmid DNA Manufacturing Market for AAV Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 19 Global Viral Vectors and Plasmid DNA Manufacturing Market for AAV Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 20 Global Viral Vectors and Plasmid DNA Manufacturing Market for AAV Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 21 Global Viral Vectors and Plasmid DNA Manufacturing Market for Lentivirus Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 22 Global Viral Vectors and Plasmid DNA Manufacturing Market for Lentivirus Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 23 Global Viral Vectors and Plasmid DNA Manufacturing Market for Lentivirus Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 24 Global Viral Vectors and Plasmid DNA Manufacturing Market for Lentivirus Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 25 Global Viral Vectors and Plasmid DNA Manufacturing Market for Lentivirus Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 26 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 27 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 28 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 29 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 30 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 31 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 32 Global Viral Vectors and Plasmid DNA Manufacturing Market for Antisense & RNAi Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 33 Global Viral Vectors and Plasmid DNA Manufacturing Market for Antisense & RNAi Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 34 Global Viral Vectors and Plasmid DNA Manufacturing Market for Antisense & RNAi Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 35 Global Viral Vectors and Plasmid DNA Manufacturing Market for Antisense & RNAi Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 36 Global Viral Vectors and Plasmid DNA Manufacturing Market for Antisense & RNAi Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 37 The current industry-wide gene therapy pipeline can be organized by stage and therapeutic area
  • Table 38 Global Viral Vectors and Plasmid DNA Manufacturing Market for Gene Therapy Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 39 Global Viral Vectors and Plasmid DNA Manufacturing Market for Gene Therapy Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 40 Global Viral Vectors and Plasmid DNA Manufacturing Market for Gene Therapy Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 41 Global Viral Vectors and Plasmid DNA Manufacturing Market for Gene Therapy Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 42 Global Viral Vectors and Plasmid DNA Manufacturing Market for Gene Therapy Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 43 List of Cell Therapy Companies Worldwide by Location and Type
  • Table 44 Global Viral Vectors and Plasmid DNA Manufacturing Market for Cell Therapy Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 45 Global Viral Vectors and Plasmid DNA Manufacturing Market for Cell Therapy Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 46 Global Viral Vectors and Plasmid DNA Manufacturing Market for Cell Therapy Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 47 Global Viral Vectors and Plasmid DNA Manufacturing Market for Cell Therapy Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 48 Global Viral Vectors and Plasmid DNA Manufacturing Market for Cell Therapy Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 49 Global Viral Vectors and Plasmid DNA Manufacturing Market for Vaccinology Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 50 Global Viral Vectors and Plasmid DNA Manufacturing Market for Vaccinology Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 51 Global Viral Vectors and Plasmid DNA Manufacturing Market for Vaccinology Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 52 Global Viral Vectors and Plasmid DNA Manufacturing Market for Vaccinology Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 53 Global Viral Vectors and Plasmid DNA Manufacturing Market for Vaccinology Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 54 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 55 Global Viral Vectors and Plasmid DNA Manufacturing Market for Oncology Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 56 Global Viral Vectors and Plasmid DNA Manufacturing Market for Oncology Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 57 Global Viral Vectors and Plasmid DNA Manufacturing Market for Oncology Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 58 Global Viral Vectors and Plasmid DNA Manufacturing Market for Oncology Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 59 Global Viral Vectors and Plasmid DNA Manufacturing Market for Oncology Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 60 Global Viral Vectors and Plasmid DNA Manufacturing Market for Genetic Disorders Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 61 Global Viral Vectors and Plasmid DNA Manufacturing Market for Genetic Disorders Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 62 Global Viral Vectors and Plasmid DNA Manufacturing Market for Genetic Disorders Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 63 Global Viral Vectors and Plasmid DNA Manufacturing Market for Genetic Disorders Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 64 Global Viral Vectors and Plasmid DNA Manufacturing Market for Genetic Disorders Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 65 Global Viral Vectors and Plasmid DNA Manufacturing Market for Infectious Diseases Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 66 Global Viral Vectors and Plasmid DNA Manufacturing Market for Infectious Diseases Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 67 Global Viral Vectors and Plasmid DNA Manufacturing Market for Infectious Diseases Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 68 Global Viral Vectors and Plasmid DNA Manufacturing Market for Infectious Diseases Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 69 Global Viral Vectors and Plasmid DNA Manufacturing Market for Infectious Diseases Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 70 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 71 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 72 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 73 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 74 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 75 Global Viral Vectors and Plasmid DNA Manufacturing Market for Pharma & Biopharma Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 76 Global Viral Vectors and Plasmid DNA Manufacturing Market for Pharma & Biopharma Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 77 Global Viral Vectors and Plasmid DNA Manufacturing Market for Pharma & Biopharma Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 78 Global Viral Vectors and Plasmid DNA Manufacturing Market for Pharma & Biopharma Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 79 Global Viral Vectors and Plasmid DNA Manufacturing Market for Pharma & Biopharma Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 80 Global Viral Vectors and Plasmid DNA Manufacturing Market for Research Institutes Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 81 Global Viral Vectors and Plasmid DNA Manufacturing Market for Research Institutes Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 82 Global Viral Vectors and Plasmid DNA Manufacturing Market for Research Institutes Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 83 Global Viral Vectors and Plasmid DNA Manufacturing Market for Research Institutes Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 84 Global Viral Vectors and Plasmid DNA Manufacturing Market for Research Institutes Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 85 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 86 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 87 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 88 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 89 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 90 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 91 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 92 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 93 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 94 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 95 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 96 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 97 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 98 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 99 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 100 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 101 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 102 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 103 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 104 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 105 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 106 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 107 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 108 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 109 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 110 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 111 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 112 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 113 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 114 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 115 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 116 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 117 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 118 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 119 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 120 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 121 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 122 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 123 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 124 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 125 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 126 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 127 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 128 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 129 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 130 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 131 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 132 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 133 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 134 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 135 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 136 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 137 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 138 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 139 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 140 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 141 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 142 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 143 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 144 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 145 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 146 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 147 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 148 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 149 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 150 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 151 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 152 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 153 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 154 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 155 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 156 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 157 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 158 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 159 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 160 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 161 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 162 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 163 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 164 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 165 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 166 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 167 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 168 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 169 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 170 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 171 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 172 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 173 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 174 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 175 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 176 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 177 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 178 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 179 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 180 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 181 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 182 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 183 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 184 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 185 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 186 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 187 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 188 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 189 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 190 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 191 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 192 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 193 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 194 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 195 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 196 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 197 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 198 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 199 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 200 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 201 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 202 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 203 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 204 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 205 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 206 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 207 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 208 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 209 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 210 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 211 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 212 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 213 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 214 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 215 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 216 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 217 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 218 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 219 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 220 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 221 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 222 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 223 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 224 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 225 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 226 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 227 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 228 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 229 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 230 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 231 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 232 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 233 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 234 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 235 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 236 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 237 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 238 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 239 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 240 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 241 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 242 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 243 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 244 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 245 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 246 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 247 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 248 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 249 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 250 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 251 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 252 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 253 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 254 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 255 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 256 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 257 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 258 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 259 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 260 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 261 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 262 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 263 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 264 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 265 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 266 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 267 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 268 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 269 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 270 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 271 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 272 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 273 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 274 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 275 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 276 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 277 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 278 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 279 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 280 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 281 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 282 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 283 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 284 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 285 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 286 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 287 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 288 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 289 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 290 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 291 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 292 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 293 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 294 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 295 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 296 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 297 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 298 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 299 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 300 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 301 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 302 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 303 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 304 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 305 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 306 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 307 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 308 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 309 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 310 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 311 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 312 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 313 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 314 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 315 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 316 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 317 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 318 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 319 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 320 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 321 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 322 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%)
  • Table 323 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 324 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 325 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 326 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 327 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 328 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 329 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 330 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ mn, AGR%, CAGR%)
  • Table 331 Merck KGaA: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 332 Merck KGaA: Product Portfolio
  • Table 333 Merck KGaA: Recent Developments
  • Table 334 Lonza: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 335 Lonza: Product Portfolio
  • Table 336 Lonza: Recent Developments
  • Table 337 FUJIFILM Diosynth Biotechnologies U.S.A., Inc: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 338 FUJIFILM Diosynth Biotechnologies U.S.A., Inc: Product Portfolio
  • Table 339 FUJIFILM Diosynth Biotechnologies U.S.A., Inc: Recent Developments
  • Table 340 Cobra Biologics Ltd.: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 341 Cobra Biologics Ltd.: Product Portfolio
  • Table 342 Cobra Biologics Ltd.: Recent Developments
  • Table 343 Brammer Bio: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 344 Brammer Bio: Product Portfolio
  • Table 345 Brammer Bio: Recent Developments
  • Table 346 Waisman Biomanufacturing: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 347 Waisman Biomanufacturing: Product Portfolio
  • Table 348 Genezen: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 349 Genezen: Product Portfolio
  • Table 350 Genezen: Recent Developments
  • Table 351 YPOSKESI: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 352 YPOSKESI: Product Portfolio
  • Table 353 YPOSKESI: Recent Developments
  • Table 354 Advanced BioScience Laboratories, Inc. (ABL, Inc.): Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 355 Advanced BioScience Laboratories, Inc. (ABL, Inc.): Product Portfolio
  • Table 356 Advanced BioScience Laboratories, Inc. (ABL, Inc.): Recent Developments
  • Table 357 Novasep Holding S.A.S: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 358 Novasep Holding S.A.S: Product Portfolio
  • Table 359 Novasep Holding S.A.S: Recent Developments
  • Table 360 ATVIO Biotech Ltd: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 361 ATVIO Biotech Ltd: Product Portfolio
  • Table 362 ATVIO Biotech Ltd: Recent Developments
  • Table 363 Vigene Biosciences, Inc: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 364 Vigene Biosciences, Inc: Product Portfolio
  • Table 365 Vigene Biosciences, Inc: Recent Developments
  • Table 366 Cytiva: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 367 Cytiva: Recent Developments
  • Table 368 CEVEC Pharmaceuticals GmbH: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 369 CEVEC Pharmaceuticals GmbH: Product Portfolio
  • Table 370 CEVEC Pharmaceuticals GmbH: Recent Developments
  • Table 371 Batavia Biosciences B.V: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 372 Batavia Biosciences B.V: Product Portfolio
  • Table 373 Batavia Biosciences B.V: Recent Developments
  • Table 374 Biovian Oy: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 375 Biovian Oy: Product Portfolio
  • Table 376 Wuxi AppTec Co., Ltd.: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 377 Wuxi AppTec Co., Ltd.: Product Portfolio
  • Table 378 Wuxi AppTec Co., Ltd.: Recent Developments
  • Table 379 VGXI, Inc.: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 380 VGXI, Inc.: Product Portfolio
  • Table 381 Paragon Bioservices, Inc.: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 382 Paragon Bioservices, Inc.: Product Portfolio
  • Table 383 Paragon Bioservices, Inc.: Recent Developments
  • Table 384 Miltenyi Biotec GmbH: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 385 SIRION Biotech GmbH: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 386 SIRION Biotech GmbH: Product Portfolio
  • Table 387 Virovek Incorporation: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 388 Virovek Incorporation: Product Portfolio
  • Table 389 BioNTech IMFS GmbH: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 390 BioNTech IMFS GmbH: Product Portfolio
  • Table 391 VIVEbiotech S.L.: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 392 VIVEbiotech S.L.: Product Portfolio
  • Table 393 VIVEbiotech S.L.: Recent Developments
  • Table 394 Creative Biogene: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 395 Creative Biogene: Product Portfolio
  • Table 396 Creative Biogene: Recent Developments
  • Table 397 Vibalogics GmbH: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 398 Vibalogics GmbH: Product Portfolio
  • Table 399 Vibalogics GmbH: Recent Developments
  • Table 400 Cell and Gene Therapy Catapult: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 401 BlueBird Bio: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 402 Addgene, Inc.: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 403 Addgene, Inc.: Product Portfolio
  • Table 404 Addgene, Inc.: Recent Developments
  • Table 405 Aldevron, L.L.C.: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 406 Aldevron, L.L.C.: Product Portfolio
  • Table 407 Audentes Therapeutics: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 408 Audentes Therapeutics: Recent Developments
  • Table 409 BioMarin Pharmaceutical: Key Details, 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 410 BioMarin Pharmaceutical: Recent Developments

List of Figures

  • Figure 1 Global Viral Vectors and Plasmid DNA Manufacturing Market: Market Trends
  • Figure 2 Cell and gene therapy modalities
  • Figure 3 COVID-19 vaccine pipeline by type
  • Figure 4 Porter's Analysis
  • Figure 5 Upstream Analysis
  • Figure 6 Downstream Analysis
  • Figure 7 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 8 Global Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Types, 2021, 2026, 2031 (%)
  • Figure 9 Global Viral Vectors and Plasmid DNA Manufacturing Market for Adenovirus Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 10 Global Viral Vectors and Plasmid DNA Manufacturing Market for Adenovirus Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 11 Global Viral Vectors and Plasmid DNA Manufacturing Market for Adenovirus Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 12 Global Viral Vectors and Plasmid DNA Manufacturing Market for Adenovirus Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 13 Global Viral Vectors and Plasmid DNA Manufacturing Market for Adenovirus Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 14 Global Viral Vectors and Plasmid DNA Manufacturing Market for Retrovirus Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 15 Global Viral Vectors and Plasmid DNA Manufacturing Market for Retrovirus Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 16 Global Viral Vectors and Plasmid DNA Manufacturing Market for Retrovirus Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 17 Global Viral Vectors and Plasmid DNA Manufacturing Market for Retrovirus Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 18 Global Viral Vectors and Plasmid DNA Manufacturing Market for Retrovirus Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 19 Global Viral Vectors and Plasmid DNA Manufacturing Market for Plasmid DNA Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 20 Global Viral Vectors and Plasmid DNA Manufacturing Market for Plasmid DNA Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 21 Global Viral Vectors and Plasmid DNA Manufacturing Market for Plasmid DNA Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 22 Global Viral Vectors and Plasmid DNA Manufacturing Market for Plasmid DNA Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 23 Global Viral Vectors and Plasmid DNA Manufacturing Market for Plasmid DNA Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 24 Global Viral Vectors and Plasmid DNA Manufacturing Market for AAV Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 25 Global Viral Vectors and Plasmid DNA Manufacturing Market for AAV Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 26 Global Viral Vectors and Plasmid DNA Manufacturing Market for AAV Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 27 Global Viral Vectors and Plasmid DNA Manufacturing Market for AAV Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 28 Global Viral Vectors and Plasmid DNA Manufacturing Market for AAV Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 29 Global Viral Vectors and Plasmid DNA Manufacturing Market for Lentivirus Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 30 Global Viral Vectors and Plasmid DNA Manufacturing Market for Lentivirus Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 31 Global Viral Vectors and Plasmid DNA Manufacturing Market for Lentivirus Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 32 Global Viral Vectors and Plasmid DNA Manufacturing Market for Lentivirus Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 33 Global Viral Vectors and Plasmid DNA Manufacturing Market for Lentivirus Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 34 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 35 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 36 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 37 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 38 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 39 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 40 Global Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Types, 2021, 2026, 2031 (%)
  • Figure 41 Global Viral Vectors and Plasmid DNA Manufacturing Market for Antisense & RNAi Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 42 Global Viral Vectors and Plasmid DNA Manufacturing Market for Antisense & RNAi Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 43 Global Viral Vectors and Plasmid DNA Manufacturing Market for Antisense & RNAi Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 44 Global Viral Vectors and Plasmid DNA Manufacturing Market for Antisense & RNAi Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 45 Global Viral Vectors and Plasmid DNA Manufacturing Market for Antisense & RNAi Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 46 Global Viral Vectors and Plasmid DNA Manufacturing Market for Gene Therapy Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 47 Global Viral Vectors and Plasmid DNA Manufacturing Market for Gene Therapy Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 48 Global Viral Vectors and Plasmid DNA Manufacturing Market for Gene Therapy Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 49 Global Viral Vectors and Plasmid DNA Manufacturing Market for Gene Therapy Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 50 Global Viral Vectors and Plasmid DNA Manufacturing Market for Gene Therapy Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 51 Global Viral Vectors and Plasmid DNA Manufacturing Market for Cell Therapy Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 52 Global Viral Vectors and Plasmid DNA Manufacturing Market for Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 53 Global Viral Vectors and Plasmid DNA Manufacturing Market for Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 54 Global Viral Vectors and Plasmid DNA Manufacturing Market for Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 55 Global Viral Vectors and Plasmid DNA Manufacturing Market for Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 56 Global Viral Vectors and Plasmid DNA Manufacturing Market for Vaccinology Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 57 Global Viral Vectors and Plasmid DNA Manufacturing Market for Vaccinology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 58 Global Viral Vectors and Plasmid DNA Manufacturing Market for Vaccinology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 59 Global Viral Vectors and Plasmid DNA Manufacturing Market for Vaccinology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 60 Global Viral Vectors and Plasmid DNA Manufacturing Market for Vaccinology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 61 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 62 Global Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Disease, 2021, 2026, 2031 (%)
  • Figure 63 Global Viral Vectors and Plasmid DNA Manufacturing Market for Oncology Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 64 Global Viral Vectors and Plasmid DNA Manufacturing Market for Oncology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 65 Global Viral Vectors and Plasmid DNA Manufacturing Market for Oncology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 66 Global Viral Vectors and Plasmid DNA Manufacturing Market for Oncology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 67 Global Viral Vectors and Plasmid DNA Manufacturing Market for Oncology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 68 Global Viral Vectors and Plasmid DNA Manufacturing Market for Genetic Disorders Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 69 Global Viral Vectors and Plasmid DNA Manufacturing Market for Genetic Disorders Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 70 Global Viral Vectors and Plasmid DNA Manufacturing Market for Genetic Disorders Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 71 Global Viral Vectors and Plasmid DNA Manufacturing Market for Genetic Disorders Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 72 Global Viral Vectors and Plasmid DNA Manufacturing Market for Genetic Disorders Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 73 Global Viral Vectors and Plasmid DNA Manufacturing Market for Infectious Diseases Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 74 Global Viral Vectors and Plasmid DNA Manufacturing Market for Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 75 Global Viral Vectors and Plasmid DNA Manufacturing Market for Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 76 Global Viral Vectors and Plasmid DNA Manufacturing Market for Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 77 Global Viral Vectors and Plasmid DNA Manufacturing Market for Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 78 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 79 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 80 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 81 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 82 Global Viral Vectors and Plasmid DNA Manufacturing Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 83 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 84 Global Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-Use, 2021, 2026, 2031 (%)
  • Figure 85 Global Viral Vectors and Plasmid DNA Manufacturing Market for Pharma and Biopharma Companies Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 86 Global Viral Vectors and Plasmid DNA Manufacturing Market for Pharma and Biopharma Companies Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 87 Global Viral Vectors and Plasmid DNA Manufacturing Market for Pharma and Biopharma Companies Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 88 Global Viral Vectors and Plasmid DNA Manufacturing Market for Pharma and Biopharma Companies Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 89 Global Viral Vectors and Plasmid DNA Manufacturing Market for Pharma and Biopharma Companies Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 90 Global Viral Vectors and Plasmid DNA Manufacturing Market for Research Institutes Segment: Revenue Forecast 2021-2031 (US$ million, AGR%)
  • Figure 91 Global Viral Vectors and Plasmid DNA Manufacturing Market for Research Institutes Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 92 Global Viral Vectors and Plasmid DNA Manufacturing Market for Research Institutes Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 93 Global Viral Vectors and Plasmid DNA Manufacturing Market for Research Institutes Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 94 Global Viral Vectors and Plasmid DNA Manufacturing Market for Research Institutes Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 95 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2021-2031 (US$ million)
  • Figure 96 Global Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Region 2021, 2026, 2031 (%)
  • Figure 97 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 98 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 99 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 100 Global Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 101 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country 2021-2031 (US$ million)
  • Figure 102 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 103 North America Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 104 North America Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 105 North America Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 106 North America Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 107 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 108 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 109 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 110 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 111 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 112 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 113 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 114 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 115 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 116 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 117 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 118 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 119 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 120 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 121 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 122 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 123 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 124 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 125 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 126 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 127 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 128 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 129 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 130 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 131 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 132 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 133 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 134 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 135 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 136 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 137 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 138 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 139 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 140 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 141 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 142 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 143 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 144 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 145 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country 2021-2031 (US$ million)
  • Figure 146 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 147 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 148 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 149 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 150 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 151 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 152 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 153 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 154 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 155 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 156 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 157 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 158 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 159 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 160 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 161 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 162 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 163 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 164 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 165 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 166 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 167 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 168 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 169 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 170 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 171 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 172 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 173 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 174 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 175 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 176 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 177 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 178 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 179 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 180 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 181 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 182 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 183 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 184 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 185 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 186 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 187 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 188 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 189 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 190 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 191 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 192 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 193 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 194 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 195 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 196 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 197 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 198 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country 2021-2031 (US$ million)
  • Figure 199 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 200 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 201 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 202 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 203 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 204 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 205 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 206 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 207 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 208 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 209 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 210 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 211 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 212 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 213 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 214 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 215 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 216 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 217 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 218 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 219 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 220 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 221 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 222 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 223 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 224 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 225 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 226 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 227 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 228 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 229 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 230 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 231 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 232 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 233 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 234 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 235 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 236 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 237 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 238 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 239 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 240 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 241 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 242 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 243 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 244 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 245 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 246 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 247 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 248 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 249 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 250 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 251 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 252 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 253 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 254 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 255 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 256 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 257 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 258 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 259 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 260 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country 2021-2031 (US$ million)
  • Figure 261 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 262 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 263 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 264 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 265 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 266 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 267 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 268 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 269 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 270 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 271 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 272 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 273 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 274 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 275 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 276 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 277 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 278 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 279 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 280 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 281 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 282 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 283 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 284 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 285 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 286 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 287 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 288 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 289 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 290 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 291 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 292 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 293 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 294 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 295 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 296 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 297 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 298 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 299 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 300 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 301 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 302 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 303 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 304 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country 2021-2031 (US$ million)
  • Figure 305 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 306 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 307 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 308 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 309 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market by Country, Revenue Forecast 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 310 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 311 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 312 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 313 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 314 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 315 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 316 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 317 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 318 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 319 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 320 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 321 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 322 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 323 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 324 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 325 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 326 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 327 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 328 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 329 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 330 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 331 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 332 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 333 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 334 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 335 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 336 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 337 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 338 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 339 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR %)
  • Figure 340 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "V" Shaped Recovery
  • Figure 341 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "U" Shaped Recovery
  • Figure 342 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "W" Shaped Recovery
  • Figure 343 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2021-2031 (US$ million, AGR%): "L" Shaped Recovery
  • Figure 344 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Types, 2021-2031 (US$ million, AGR %)
  • Figure 345 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2021-2031 (US$ million, AGR %)
  • Figure 346 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2021-2031 (US$ million, AGR %)
  • Figure 347 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-Use, 2021-2031 (US$ million, AGR %)
  • Figure 348 Merck KGaA.: Net Revenue, 2015-2019 (US$ Mn, AGR%)
  • Figure 349 Lonza.: Net Revenue, 2015-2019 (US$ Mn, AGR%)
  • Figure 350 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.: Net Revenue, 2015-2019 (US$ Mn, AGR%)
  • Figure 351 BioMarin Pharmaceutical.: Net Revenue, 2015-2019 (US$ Mn, AGR%)

COMPANIES LISTED:

  • Companies Profiled in the Report
  • Addgene, Inc.
  • Advanced BioScience Laboratories, Inc. (ABL, Inc.)
  • Aldevron, L.L.C.
  • ATVIO Biotech Ltd
  • Audentes Therapeutics
  • Batavia Biosciences B.V
  • BioMarin Pharmaceutical
  • BioNTech IMFS GmbH
  • Biovian Oy
  • BlueBird Bio
  • Brammer Bio
  • Cell and Gene Therapy Catapult
  • CEVEC Pharmaceuticals GmbH
  • Cobra Biologics Ltd.
  • Creative Biogene
  • Cytiva
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Genezen
  • Lonza
  • Merck KGaA
  • Miltenyi Biotec GmbH
  • Novasep Holding S.A.S
  • Paragon Bioservices, Inc.
  • SIRION Biotech GmbH
  • VGXI, Inc.
  • Vibalogics GmbH
  • Vigene Biosciences, Inc.
  • Virovek Incorporation
  • VIVEbiotech S.L.
  • Waisman Biomanufacturing
  • Wuxi AppTec Co., Ltd.
  • YPOSKESI

List of Other Companies

  • Abeona Therapeutics
  • Acucela
  • Adaptimmune Therapeutics
  • Autolus
  • AveXis
  • BioCancell
  • Biomay
  • Biomiga
  • BioReliance
  • Biotec Services International
  • Celladon
  • Cellectis
  • Cellular Biomedicine Group
  • Delphi Genetics
  • Department of Neuroscience, University of Minnesota
  • Desktop Genetics
  • DNAtrix
  • Elixirgen Scientific
  • Epeius Biotechnologies
  • EUFETS
  • Eurofins Genomics
  • European Society of Gene and Cell Therapy
  • GEG Tech
  • Genable Technologies
  • Immune Design
  • Immune Technology
  • ImmunoGenes
  • Immunomic Therapeutics
  • Inbiomed
  • Indiana University Vector Production Facility
  • VIVEbiotech
  • Voyager Therapeutics
  • Waisman Biomanufacturing
  • Xpress Biologics

List of Organizations Mentioned in the Report

  • c-LEcta GmbH
  • Gene Therapy Net
  • Informa UK Limited
  • IntechOpen
  • JOURNAL OF GENERAL VIROLOGY
  • Massachusetts Medical Society
  • National Center for Biotechnology Information
  • Pan European Networks Ltd
  • Pharma Manufacturing
  • Pharmaceutical-Networking.com
  • The Alliance for Regenerative Medicine
  • The Royal Society
  • Transgene
  • University of Rochester
  • x Labiotech UG